M
Matthew J. Olnes
Researcher at Alaska Native Tribal Health Consortium
Publications - 44
Citations - 2077
Matthew J. Olnes is an academic researcher from Alaska Native Tribal Health Consortium. The author has contributed to research in topics: Eltrombopag & Myelodysplastic syndromes. The author has an hindex of 16, co-authored 44 publications receiving 1749 citations. Previous affiliations of Matthew J. Olnes include National Institutes of Health & Alaska Native Medical Center.
Papers
More filters
Journal ArticleDOI
Eltrombopag and Improved Hematopoiesis in Refractory Aplastic Anemia
Matthew J. Olnes,Phillip Scheinberg,Katherine R. Calvo,Ronan Desmond,Yong Tang,Bogdan Dumitriu,Ankur R. Parikh,Susan Soto,Angelique Biancotto,Xingmin Feng,Jay N. Lozier,Colin O. Wu,Neal S. Young,Cynthia E. Dunbar +13 more
TL;DR: Treatment with eltrombopag was associated with multilineage clinical responses in some patients with refractory severe aplastic anemia and may improve blood counts.
Journal ArticleDOI
Global analyses of human immune variation reveal baseline predictors of postvaccination responses.
John S. Tsang,Pamela L. Schwartzberg,Yuri Kotliarov,Angelique Biancotto,Zhi Xie,Ronald N. Germain,Ena Wang,Matthew J. Olnes,Manikandan Narayanan,Hana Golding,Susan Moir,Howard B. Dickler,Shira Perl,Foo Cheung +13 more
TL;DR: Independent of age and pre-existing antibody titers, accurate models could be constructed using pre-perturbation cell populations alone, which were validated using independent baseline time points.
Journal ArticleDOI
Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug
Ronan Desmond,Danielle M. Townsley,Bogdan Dumitriu,Matthew J. Olnes,Phillip Scheinberg,Margaret Bevans,Ankur R. Parikh,Kinneret Broder,Katherine R. Calvo,Colin O. Wu,Neal S. Young,Cynthia E. Dunbar +11 more
TL;DR: Eltrombopag is efficacious in a subset of patients with aplastic anemia refractory to immunosuppressive therapy, with frequent multilineage responses and maintenance of normalized hematopoiesis off treatment.
Journal ArticleDOI
Effects of Systemically Administered Hydrocortisone on the Human Immunome.
Matthew J. Olnes,Matthew J. Olnes,Yuri Kotliarov,Angelique Biancotto,Foo Cheung,Jinguo Chen,Rongye Shi,Huizhi Zhou,Ena Wang,Ena Wang,John S. Tsang,Robert B. Nussenblatt +11 more
TL;DR: This study is the first to systematically characterize the effects of corticosteroids on the human immunome, and it is demonstrated that HC exerts differential effects on B and T lymphocytes and natural killer cells in humans.
Journal ArticleDOI
Alemtuzumab Treatment of Intermediate-1 Myelodysplasia Patients Is Associated With Sustained Improvement in Blood Counts and Cytogenetic Remissions
Elaine M. Sloand,Matthew J. Olnes,A. Shenoy,Barbara Weinstein,Carol Boss,Kelsey B. Loeliger,Colin O. Wu,Kenneth More,A. John Barrett,Phillip Scheinberg,Neal S. Young +10 more
TL;DR: Alemtuzumab is safe and active in MDS and may be an attractive alternative to ATG in selected patients likely to respond to IST, which is a nonrandomized, off-label, pilot, phase I/II study.